Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-EHA 2025 MPNs Highlights
25 June 2025 | Virtual Meeting
Post-EHA 2025 MPNs Highlights
Featuring presentations & discussions on selected MPN abstracts from the 30th Congress of the European Hematology Association (EHA).
Chair: Claire Harrison
Moderators: John Mascarenhas & Jean-Jacques Kiladjian
The Post-EHA 2025 MPN’s webinar has been supported by a silver sponsorship from Sumitomo Pharma and an educational grant from Blueprint Medicines. Supporters have had no influence over the production of this activity.
Session 1: Molecular and clinical stratification in MPNs and mastocytosis
Identification of ultra high-risk genotypes for progression to blast phase disease redefines molecular-based stratification of myelofibrosis
Noushin Farnoud Memorial Sloan Kettering Cancer Center, New York, NY, United States
QRISK3 score identifies essential thrombocythemia and polycythemia vera patients who benefit from cytoreductive therapy
Andrea Duminuco University of Catania, Catania, Italy
Genomic profiling for clinical decision making in post-polycythemia vera and post-essential thrombocythemia
Barbara Mora University of Milan, Milan, Italy
The revised mutation-adjusted risk score (MARS-R) for predicting overall survival in patients with advanced systemic mastocytosis treated with midostaurin or avapritinib
Johannes Lübke Heidelberg University, Heidelberg, , Germany
Panel discussion
Session 2: RWE and evolving approaches in MF therapy
Retrospective analysis of efficacy and safety outcomes in patients with primary and secondary myelofibrosis treated with ruxolitinib: JUMP study
Haifa Kathrin Al-Ali Martin Luther University of Halle-Wittenberg, Halle, Germany
Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia supporting medications
Pankit Vachhani The University of Alabama at Birmingham, Birmingham, AL, United States
Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosis
Harry Gill Queen Mary Hospital, Pok Fu Lam, Hong Kong
Panel discussion
Session 3: Therapeutic advances and clinical outcomes in MPNs
Clinical characteristics and survival of 312 patients with MPL-mutant essential thrombocythemia: An international European LeukemiaNet collaborative study
Steffen Koschmieder Aachen University Hospital, Aachen, Germany
SANRECO, an on-going Phasel/ll study evaluating divesiran, a novel GalNAc-conjugated siRNA, in patients with polycythemia vera
Marina Kremyanskaya Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Better safety and efficacy with ropeginterferon alfa-2b over anagrelide as second-line treatment of essential thrombocythemia in the topline results of the randomized Phase lll SURPASS-ET trial
Harry Gill Queen Mary Hospital, Pok Fu Lam, Hong Kong
INCA33989 is a novel, first in class, mutant calreticulin-specific monoclonal antibody that demonstrates safety and efficacy in patients with essential thrombocythemia (ET)
John Mascarenhas Icahn School of Medicine at Mount Sinai, New York City, NY, United States
Panel discussion
Session 4: Special populations and monitoring strategies for MPNs
MyMPNvoice app: Remote longitudinal monitoring of patient reported outcomes and biometrics in patients with myeloproliferative neoplasms
Patrick Harrington Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Fibrosis grade before and its resolution after transplantation has no predictive value in myelofibrosis
Nico Gagelmann University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Protective effect of acetylsalicylic acid and interferon alpha on live birth rate in myeloproliferative neoplasms: A meta-analysis based on the systematic review of 1,697 pregnancies
Monia Marchetti Ospedale Cardinal Massaia, Asti, Italy
Panel discussion
